These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 18297955

  • 21. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
    Albo D, Farrow B, Berger DH.
    Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
    [Abstract] [Full Text] [Related]

  • 22. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ, Goodin S.
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [Abstract] [Full Text] [Related]

  • 23. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.
    Svoboda M, Poprach A, Dobes S, Kiss I, Vyzula R.
    Cardiovasc Toxicol; 2012 Sep; 12(3):191-207. PubMed ID: 22528816
    [Abstract] [Full Text] [Related]

  • 24. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA.
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [Abstract] [Full Text] [Related]

  • 25. [New frontiers in cancer treatment].
    Tortora G, Daniele G.
    Recenti Prog Med; 2006 Dec; 97(12):781-6. PubMed ID: 17252737
    [Abstract] [Full Text] [Related]

  • 26. Targeted cancer. These "smart weapons" hit cancer in novel ways.
    Held-Warmkessel J.
    Nursing; 2008 Sep; 38(9):26-32. PubMed ID: 18719487
    [Abstract] [Full Text] [Related]

  • 27. Clinical approaches to minimize rash associated with EGFR inhibitors.
    Oishi K.
    Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
    [Abstract] [Full Text] [Related]

  • 28. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E, Henri P, de Raucourt S, Lireux B, Lamy E, Delcambre C, Sevin E, Dutriaux C, Bouhier-Leporrier K, Gervais R, Joly F.
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [Abstract] [Full Text] [Related]

  • 29. Rational targeting of Notch signaling in cancer.
    Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L.
    Oncogene; 2008 Sep 01; 27(38):5124-31. PubMed ID: 18758481
    [Abstract] [Full Text] [Related]

  • 30. The era of targeted therapies.
    Offermann M.
    Am Fam Physician; 2008 Feb 01; 77(3):294, 296. PubMed ID: 18297954
    [No Abstract] [Full Text] [Related]

  • 31. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL, Andersson M, Kamby C.
    Cancer Treat Rev; 2009 Apr 01; 35(2):121-36. PubMed ID: 19008049
    [Abstract] [Full Text] [Related]

  • 32. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues.
    Christoffersen T, Guren TK, Spindler KL, Dahl O, Lønning PE, Gjertsen BT.
    Eur J Pharmacol; 2009 Dec 25; 625(1-3):6-22. PubMed ID: 19836383
    [Abstract] [Full Text] [Related]

  • 33. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH.
    Am Heart J; 2012 Feb 25; 163(2):156-63. PubMed ID: 22305831
    [Abstract] [Full Text] [Related]

  • 34. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
    Lang A, Graeven U.
    Zentralbl Chir; 2009 Jun 25; 134(3):189-92. PubMed ID: 19544236
    [No Abstract] [Full Text] [Related]

  • 35. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD, Moehler M.
    Curr Opin Oncol; 2009 Jul 25; 21(4):381-5. PubMed ID: 19412098
    [Abstract] [Full Text] [Related]

  • 36. Comparing antibody and small-molecule therapies for cancer.
    Imai K, Takaoka A.
    Nat Rev Cancer; 2006 Sep 25; 6(9):714-27. PubMed ID: 16929325
    [Abstract] [Full Text] [Related]

  • 37. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
    Eremina V, Quaggin SE.
    Semin Nephrol; 2010 Nov 25; 30(6):582-90. PubMed ID: 21146123
    [Abstract] [Full Text] [Related]

  • 38. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
    Carles J, Morales R, Perez JM, Suárez C, Rodón J, Valverde C.
    Eur J Cancer; 2009 Sep 25; 45 Suppl 1():309-17. PubMed ID: 19775627
    [No Abstract] [Full Text] [Related]

  • 39. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.
    Chen MH, Kerkelä R, Force T.
    Circulation; 2008 Jul 01; 118(1):84-95. PubMed ID: 18591451
    [No Abstract] [Full Text] [Related]

  • 40. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Lambert JM.
    Curr Opin Pharmacol; 2005 Oct 01; 5(5):543-9. PubMed ID: 16087399
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.